SCHEMBL24256415

SCHEMBL24256415

CC(C)c1nc2sc3c(NCc4ccco4)ncnc3c2c2c1CCC2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.73
KDM4E B2RXH2 8/20 0.73
HPGD P15428 7/20 0.73
HTT P42858 7/20 0.73
RXFP1 Q9HBX9 4/20 0.73
MAPT P10636 4/20 0.73
POLB P06746 6/20 0.66
MAPK1 P28482 4/20 0.66
NPSR1 Q6W5P4 4/20 0.66
KMT2A Q03164 4/20 0.66
MEN1 O00255 3/20 0.66
L3MBTL1 Q9Y468 2/20 0.66
PKM P14618 1/20 0.66
ADRB2 P07550 1/20 0.60
LMNA P02545 2/20 0.60
THRB P10828 1/20 0.60
HIF1A Q16665 1/20 0.60
REN P00797 1/20 0.53
TSHR P16473 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256346 0.85 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL5012337 0.84 KDM4E (1.00) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL4176858 0.78 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL24256385 0.76 KDM4E (0.75) ALDH1A1KDM4EHPGDHTTPOLB
SCHEMBL4047003 0.76 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL24256377 0.75 KDM4E (0.67) ALDH1A1KDM4EHPGDHTTPOLB
SCHEMBL4045934 0.75 PDE4B (0.67) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL5135624 0.74 KDM4E (0.83) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL5013033 0.73 KDM4E (0.80) ALDH1A1KDM4EHPGDHTTRXFP1
SCHEMBL4044358 0.73 KDM4E (0.60) ALDH1A1KDM4EHPGDHTTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 ALDH1A1 1934/4885KDM4E 1927/4885HPGD 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.